Success Metrics

Clinical Success Rate
50.0%

Based on 3 completed trials

Completion Rate
50%(3/6)
Active Trials
0(0%)
Results Posted
67%(2 trials)
Terminated
3(33%)

Phase Distribution

Ph phase_2
4
44%
Ph phase_1
5
56%

Phase Distribution

5

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
5(55.6%)
Phase 2Efficacy & side effects
4(44.4%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

37.5%

3 of 8 finished

Non-Completion Rate

62.5%

5 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(3)
Terminated(5)
Other(1)

Detailed Status

Terminated3
Completed3
Withdrawn2
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 15 (55.6%)
Phase 24 (44.4%)

Trials by Status

terminated333%
suspended111%
withdrawn222%
completed333%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_1

Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors

NCT01283945
completedphase_2

A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer

NCT02053636
terminatedphase_1

A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)

NCT03992131
withdrawnphase_1

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

NCT04151563
suspendedphase_1

A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor

NCT04042116
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT01283945Phase 1

Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors

Completed
NCT02053636Phase 2

A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer

Completed
NCT03992131Phase 1

A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)

Terminated
NCT04151563Phase 1

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

Withdrawn
NCT04042116Phase 1

A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor

Suspended
NCT02202746Phase 2

A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer

Terminated
NCT02109016Phase 2

A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations

Terminated
NCT02747797Phase 2

Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations

Withdrawn
NCT03117101Phase 1

Study of the AL3810 in the Treatment of Advanced Solid Tumor

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9